After Weight Loss: Building a GLP-1 Maintenance Plan

Reaching a meaningful weight goal can bring a welcome shift in focus. Instead of asking how much more to lose, the conversation becomes how to maintain progress while supporting energy, nutrition, and long-term health.

A maintenance plan belongs in the discussion early. Haptic patients considering semaglutide or tirzepatide can ask how follow-up will change once weight stabilizes, what happens if side effects appear, and how medication access affects the plan.

What happens when treatment stops?

In an extension of the STEP 1 study, participants who had received semaglutide regained, on average, about two-thirds of their prior weight loss during the year after treatment ended. The structured lifestyle intervention also ended. This was an exploratory follow-up in a subset of the original study, so it does not predict exactly what any individual will experience. John Wilding and colleagues' work demonstrates why a stopping plan deserves attention. STEP 1 extension

A separate randomized withdrawal trial led by Louis Aronne found that participants continuing tirzepatide maintained and extended their weight reduction, while those switched to placebo regained substantial weight. These results support treating obesity as a condition that may require continuing care. They do not mean every patient needs an identical dose indefinitely. SURMOUNT-4 trial

New evidence on dose reduction

The 2026 SURMOUNT-MAINTAIN trial, led by Deborah Horn and colleagues and funded by Eli Lilly, compared continued maximum tolerated tirzepatide, reduction to 5 mg weekly, and placebo after an initial treatment period. Continuing the higher dose preserved more weight reduction on average; reducing to 5 mg also performed better than discontinuation. Individual responses varied, and the trial allowed rescue treatment under defined conditions. SURMOUNT-MAINTAIN

That finding creates a useful conversation about individualized maintenance. It does not establish a universal taper, support improvised injection spacing, or prove that a compounded product will reproduce the study result.

Define maintenance more broadly

Before changing anything, agree on what will be tracked. A useful visit can review weight trends, waist measurements when appropriate, symptoms, blood pressure, metabolic tests, dietary intake, and physical function. Choose the measures relevant to the original reason for treatment.

The practical questions are personal. Is the regimen affordable and manageable? Is appetite compatible with adequate meals? Has a change in work, sleep, or another medication altered the situation? Is the desired weight range realistic and sustainable?

Put the follow-up plan in writing. It should explain when to contact the clinician, when to reassess the medication, and how to respond to a sustained trend rather than one fluctuating measurement.

Safety still matters after the scale stabilizes

Maintenance does not eliminate medication precautions. Review persistent gastrointestinal symptoms, dehydration, gallbladder concerns, pregnancy plans, and other medicines. The approved product label sets out these risks and the situations that require changing or stopping treatment. Zepbound prescribing information

Patients using a compounded prescription should confirm their exact formulation and instructions with the prescriber and dispensing pharmacy. A smaller vial volume does not necessarily mean a smaller dose if the concentration changed.

Research outlook: what may come next

The maintenance evidence is becoming more specific, but unanswered questions remain about the best long-term strategy for different patients. Future studies may compare sustained dosing, dose reduction, and other approaches using outcomes beyond body weight. Until those results are established, a current prescription should not be altered to imitate an experimental schedule. This article is educational and does not provide an individual taper or dosing plan.